Pilot Clinical Trial of Fecal Microbiota Transplantation for Constipation in Parkinson's Disease

作者：Huilu Zhang, Cong Shen, Wei Lei, Jian Wang, Jun Liu, Zhaoyu Qiu · 发表于：Journal of Microbiology and Biotechnology · 年份：2025 · DOI：10.4014/jmb.2509.09029 · 被引用次数：3 · 研究领域：Gut microbiota and health、Gastrointestinal motility and disorders、Clostridium difficile and Clostridium perfringens research

IntroductionParkinson's disease (PD) is a major public health and social problem because it affects so many people and causes so many disabilities [1].This neurodegenerative disorder is typically characterized by motor dysfunctions, such as myotonia, static tremor, an abnormal gait and posture, and bradykinesia.These clinical manifestations are due to gradual loss of dopaminergic neurons within the substantia nigra pars compacta (SNpc) of basal ganglia and abnormal deposition of -Synuclein (-Syn) containing Lewy bodies [2] and they worsen overtime.On the other hand, non-motor symptoms usually precede motor symptoms for years, including constipation, pain, depression, and REM sleep behavior disorder (RBD) [3].PD is known to involve multiple molecular and cellular processes during progressing, thus making it difficult for early intervention and efficient treatment.Current treatment strategies include medications on the central dopamine system, deep brain stimulation (DBS), gene therapy and stem-cell therapy [4].Gastrointestinal manifestations, including flatulence, constipation, defecation disorders, and impaired gastrointestinal motility, are commonly observed in patients with PD.The incidence of constipation in PD, approximately 40%~50%, is most commonly occurred during the prodromal stage [5].The gut-originated theory of PD is brought up by Braak et al. that -Syn aggregates originate from the enteric nervous system (ENS) and route along vagal nerve to the hindbrain [6].This ...